comparemela.com
2
3
4
5
6
7
8
Latest Breaking News On - Enrollment criteria - Page 1 : comparemela.com
PSMA-Directed Targeted Alpha Therapy Shows Activity in Heavily Pretreated Metastatic CRPC
FPI-2265 showed promising activity in patients with metastatic castration-resistant prostate cancer which was similar to prior safety and efficacy data reported.
Houston
Texas
United-states
Ebrahim-delpassand
Nuclear-oncology-center
Enrollment-criteria
Excel-diagnostics
Aacr-annual-meeting
Crpc
Prostate-cancer
Fpi-2265
Phase-2-tatcist-trial-nct05219500-
Cadomilimab Plus Oxaliplatin and Capecitabine Leads to Survival Benefit in Gastric/GEJ Cancer
Cadomilimab plus oxaliplatin and capecitabine leads to survival benefit in gastric/GEJ adenocarcinoma, regardless of PD-L1 expression.
San-diego
California
United-states
Peking
Beijing
China
Jiafu-ji
University-hospital
China-national-medical-products-administration
Akeso-inc
Peking-university-hospital
Enrollment-criteria
Kentucky Gov. Beshear vetoes bill aimed at breaking up Jefferson County Public Schools
The Kentucky General Assembly passed the resolution, but Beshear vetoed it on Monday.
Jefferson-county
Kentucky
United-states
Andy-beshear
Effective-school-district-governance-task
Jefferson-county-public
Kentucky-general-assembly
General-assembly
Concurrent-resolution
Effective-school-district-governance-task-force
Wdrb
Drb-news
Postsurgical Keytruda Boosts Survival in Clear Cell Renal Cell Carcinoma
Patients with clear cell renal cell carcinoma had improved overall survival when treated with adjuvant Keytruda compared to placebo.
Boston
Massachusetts
United-states
Dana-farber-cancer-institute
Nancy-kohlberg
Toni-choueiri
Kidney-cancer-program
Lank-center
Harvard-medical-school
Genitourinary-oncology
Nancy-kohlberg-chair
Enrollment-criteria
Adjuvant Pembrolizumab Significantly Prolongs OS vs Placebo in ccRCC
Treatment with adjuvant pembrolizumab significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma.
Massachusetts
United-states
Boston
Dana-farber-cancer-institute
Bristol-myers-squibb
Nancy-kohlberg
Toni-choueiri
Roche-genentech
Calithera-biosciences
Sanofi-aventis
Astrazeneca
Michaelj-hennessy-associates
vimarsana © 2020. All Rights Reserved.